NASDAQ:GRAL GRAIL (GRAL) Stock Price, News & Analysis $35.19 -0.73 (-2.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$35.04 -0.14 (-0.41%) As of 07/18/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GRAIL Stock (NASDAQ:GRAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GRAIL alerts:Sign Up Key Stats Today's Range$34.80▼$36.5850-Day Range$32.89▼$51.4252-Week Range$12.33▼$63.99Volume992,106 shsAverage Volume1.16 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$31.50Consensus RatingHold Company Overview GRAIL, Inc. is a biotechnology company focused on the development and commercialization of multi-cancer early detection tests based on next-generation sequencing and advanced data science. Its flagship product, the Galleri™ test, is designed to detect signals across more than 50 cancer types via a simple blood draw. By analyzing circulating cell-free DNA (cfDNA) methylation patterns, GRAIL aims to identify cancer signals at earlier stages when treatment outcomes tend to be more favorable. Originally incubated by Illumina in 2016 and subsequently spun out as an independent entity, GRAIL has attracted funding from leading life sciences investors and formed research collaborations with academic centers and healthcare providers. The company has built CLIA-certified laboratories in the United States and established partnerships to expand clinical development programs in Europe, including the U.K., Germany and the Netherlands. GRAIL’s efforts include large-scale prospective studies to validate the clinical utility and real-world performance of its test. GRAIL’s leadership team comprises seasoned executives and scientific experts in genomics, oncology and regulatory affairs. The company is headquartered in Menlo Park, California, with additional research and operations sites in the U.S. and Europe. Through its focus on early detection, GRAIL seeks to transform cancer care by enabling physicians to intervene sooner and improve patient outcomes on a global scale.AI Generated. May Contain Errors. Read More GRAIL Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreGRAL MarketRank™: GRAIL scored higher than 14% of companies evaluated by MarketBeat, and ranked 894th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingGRAIL has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGRAIL has only been the subject of 1 research reports in the past 90 days.Read more about GRAIL's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GRAIL are expected to grow in the coming year, from ($15.15) to ($12.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRAIL is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRAIL is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRAIL has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GRAIL's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.81% of the float of GRAIL has been sold short.Short Interest Ratio / Days to CoverGRAIL has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in GRAIL has recently increased by 4.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGRAIL does not currently pay a dividend.Dividend GrowthGRAIL does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.81% of the float of GRAIL has been sold short.Short Interest Ratio / Days to CoverGRAIL has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in GRAIL has recently increased by 4.03%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.72 News SentimentGRAIL has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for GRAIL this week, compared to 7 articles on an average week.Search InterestOnly 5 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows11 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,868,412.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of GRAIL is held by insiders.Read more about GRAIL's insider trading history. Receive GRAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRAIL and its competitors with MarketBeat's FREE daily newsletter. Email Address GRAL Stock News HeadlinesGRAIL, Inc. (NASDAQ:GRAL) Major Shareholder Chun R. Ding Sells 339,800 SharesJuly 4, 2025 | insidertrades.comGRAIL, Inc. (NASDAQ:GRAL) President Joshua J. Ofman Sells 9,692 SharesJuly 2, 2025 | insidertrades.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 19 at 2:00 AM | Paradigm Press (Ad)GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA SubmissionJuly 14, 2025 | msn.comAir Jordan 6 'Bin 23' is a Bank-Breaking Grail - Release Info and Where to BuyJuly 4, 2025 | msn.com'This is the holy grail of theoretical physics.' Is the key to quantum gravity hiding in this new way to make black holes?July 1, 2025 | msn.comWhere to Find Grindylow Tooth in Tainted Grail: The Fall of AvalonJune 30, 2025 | msn.comInstitutional investors in GRAIL, Inc. (NASDAQ:GRAL) lost 9.3% last week but have reaped the benefits of longer-term growthJune 25, 2025 | finance.yahoo.comSee More Headlines GRAL Stock Analysis - Frequently Asked Questions How have GRAL shares performed this year? GRAIL's stock was trading at $17.85 on January 1st, 2025. Since then, GRAL stock has increased by 97.1% and is now trading at $35.19. How were GRAIL's earnings last quarter? GRAIL, Inc. (NASDAQ:GRAL) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The company earned $31.84 million during the quarter, compared to analysts' expectations of $35.80 million. GRAIL had a negative trailing twelve-month return on equity of 17.99% and a negative net margin of 1,464.53%. Read the conference call transcript. Who are GRAIL's major shareholders? Top institutional investors of GRAIL include Douglas Lane & Associates LLC (0.47%), Dakota Wealth Management (0.14%), Wesbanco Bank Inc. (0.12%) and Wealth Enhancement Advisory Services LLC (0.10%). Insiders that own company stock include Chun R Ding, Robert P Ragusa, Joshua J Ofman and Aaron Freidin. View institutional ownership trends. How do I buy shares of GRAIL? Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRAIL own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRAIL investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings5/13/2025Today7/19/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:GRAL Previous SymbolNASDAQ:GRAL CIK1699031 WebN/A Phone(650) 771-9796FaxN/AEmployees1,360Year FoundedN/APrice Target and Rating Average Price Target for GRAIL$31.50 High Price Target$43.00 Low Price Target$20.00 Potential Upside/Downside-10.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($60.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.03 billion Net Margins-1,464.53% Pretax Margin-1,594.58% Return on Equity-17.99% Return on Assets-15.02% Debt Debt-to-Equity RatioN/A Current Ratio9.70 Quick Ratio9.71 Sales & Book Value Annual Sales$125.60 million Price / Sales10.08 Cash Flow$28.38 per share Price / Cash Flow1.24 Book Value$74.50 per share Price / Book0.47Miscellaneous Outstanding Shares35,970,000Free Float35,307,000Market Cap$1.27 billion OptionableOptionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:GRAL) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRAIL, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRAIL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.